Clinical Trials Logo

Gynecological Malignancies clinical trials

View clinical trials related to Gynecological Malignancies.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT00770536 Completed - Cancer Clinical Trials

AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR

Start date: January 2009
Phase: Phase 1
Study type: Interventional

This study is a 2 part, 2 cohort, open-label, dose escalation/de escalation study of AMG 386 in combination with either pegylated liposomal doxorubicin or topotecan in subjects with recurrent ovarian cancer. Up to 100 subjects will be enrolled to receive AMG 386 in combination with either pegylated liposomal doxorubicin every 4 weeks (cohort A) or topotecan weekly on days 1, 8, and 15 of a 28 day dosing schedule (cohort B). Subject enrollment and assignment to either cohort will be based on eligibility and the investigator's discretion. It is hypothesized that AMG 386, in combination with each of the chemotherapy regimens: either pegylated liposomal doxorubicin or topotecan will be safe and well tolerated in subjects with recurrent ovarian cancer.

NCT ID: NCT00121030 Completed - Anemia Clinical Trials

Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia Due to Chemotherapy

Start date: October 2002
Phase: Phase 2
Study type: Interventional

The purpose of this study is to validate a Patient Satisfaction Questionnaire for Anemia Treatment (PSQ-AT) in gynecological cancer patients treated with darbepoetin alfa or recombinant human erythropoietin (rHuEPO) for anemia due to chemotherapy.